Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113749076> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2113749076 endingPage "358" @default.
- W2113749076 startingPage "355" @default.
- W2113749076 abstract "Paclitaxel (PTX) and topotecan (TPT) have shown promising antitumor activity in both ovarian cancer (OC) and small-cell lung cancer (SCLC) patients. This phase I study was aimed at determining the maximum tolerable dose (MTD) of TPT given weekly over 30 min in combination with fixed doses of cisplatin (CDDP) and (PTX), and with G-CSF support.Forty-four patients with OC (19) or SCLC (25), either chemo-naïve (20) or pretreated (24) received CDDP 40 mg/m2, PTX 85 mg/m2 (one-hour infusion) and escalating TPT doses (starting from 0.75 mg/m2) in a 30-min infusion in weekly administration. Filgrastim 5 mg/kg was administered on days 3 to 5 of each week.Eight different dose levels were tested for a total of 295 delivered cycles. The dose escalation was interrupted at the TPT dose of 2.50 mg/m2. No toxic deaths occurred in this study. Grade 3 to 4 neutropenia, thrombocytopenia, and anemia occurred in 15 patients (36 cycles), seven patients (15 cycles), and four patients (five cycles), respectively. Severe vomiting and diarrhoea occurred in seven and four patients. Peripheral neuropathy was recorded in 11 patients (42 cycles), but it was never severe. An overall 11 of 19 (58%) OC and 11 of 25 (44%) SCLC patients obtained objective responses. Eight patients showed complete responses (three OC and three SCLC). Among the 20 chemo-naïve patients, 9 of 11 (82%) OC and seven of nine (78%) SCLC responded.The CDDP/TPT/PTX weekly administration with filgrastim support represents a well-tolerated and active therapeutic approach in both chemo-naïve and pretreated OC and SCLC patients. A weekly dose of TPT of 2.25 mg/m2 is recommended for the phase II study." @default.
- W2113749076 created "2016-06-24" @default.
- W2113749076 creator A5000473694 @default.
- W2113749076 creator A5007772142 @default.
- W2113749076 creator A5015297880 @default.
- W2113749076 creator A5015849958 @default.
- W2113749076 creator A5020192377 @default.
- W2113749076 creator A5031898133 @default.
- W2113749076 creator A5038579170 @default.
- W2113749076 creator A5043924324 @default.
- W2113749076 creator A5056559714 @default.
- W2113749076 creator A5064890179 @default.
- W2113749076 creator A5065804893 @default.
- W2113749076 creator A5073695437 @default.
- W2113749076 creator A5081385647 @default.
- W2113749076 date "1999-03-01" @default.
- W2113749076 modified "2023-09-27" @default.
- W2113749076 title "Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: A dose-finding study" @default.
- W2113749076 cites W1823200579 @default.
- W2113749076 cites W1831044128 @default.
- W2113749076 cites W1913802169 @default.
- W2113749076 cites W1931620667 @default.
- W2113749076 cites W1966628327 @default.
- W2113749076 cites W2119940570 @default.
- W2113749076 cites W2260360964 @default.
- W2113749076 cites W2328421677 @default.
- W2113749076 doi "https://doi.org/10.1023/a:1008301222560" @default.
- W2113749076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10355583" @default.
- W2113749076 hasPublicationYear "1999" @default.
- W2113749076 type Work @default.
- W2113749076 sameAs 2113749076 @default.
- W2113749076 citedByCount "36" @default.
- W2113749076 countsByYear W21137490762021 @default.
- W2113749076 crossrefType "journal-article" @default.
- W2113749076 hasAuthorship W2113749076A5000473694 @default.
- W2113749076 hasAuthorship W2113749076A5007772142 @default.
- W2113749076 hasAuthorship W2113749076A5015297880 @default.
- W2113749076 hasAuthorship W2113749076A5015849958 @default.
- W2113749076 hasAuthorship W2113749076A5020192377 @default.
- W2113749076 hasAuthorship W2113749076A5031898133 @default.
- W2113749076 hasAuthorship W2113749076A5038579170 @default.
- W2113749076 hasAuthorship W2113749076A5043924324 @default.
- W2113749076 hasAuthorship W2113749076A5056559714 @default.
- W2113749076 hasAuthorship W2113749076A5064890179 @default.
- W2113749076 hasAuthorship W2113749076A5065804893 @default.
- W2113749076 hasAuthorship W2113749076A5073695437 @default.
- W2113749076 hasAuthorship W2113749076A5081385647 @default.
- W2113749076 hasBestOaLocation W21137490761 @default.
- W2113749076 hasConcept C121608353 @default.
- W2113749076 hasConcept C126322002 @default.
- W2113749076 hasConcept C2776256026 @default.
- W2113749076 hasConcept C2776694085 @default.
- W2113749076 hasConcept C2777063308 @default.
- W2113749076 hasConcept C2777292972 @default.
- W2113749076 hasConcept C2777767877 @default.
- W2113749076 hasConcept C2778239845 @default.
- W2113749076 hasConcept C2779171977 @default.
- W2113749076 hasConcept C2780427987 @default.
- W2113749076 hasConcept C2780852908 @default.
- W2113749076 hasConcept C2781209748 @default.
- W2113749076 hasConcept C71924100 @default.
- W2113749076 hasConcept C90924648 @default.
- W2113749076 hasConceptScore W2113749076C121608353 @default.
- W2113749076 hasConceptScore W2113749076C126322002 @default.
- W2113749076 hasConceptScore W2113749076C2776256026 @default.
- W2113749076 hasConceptScore W2113749076C2776694085 @default.
- W2113749076 hasConceptScore W2113749076C2777063308 @default.
- W2113749076 hasConceptScore W2113749076C2777292972 @default.
- W2113749076 hasConceptScore W2113749076C2777767877 @default.
- W2113749076 hasConceptScore W2113749076C2778239845 @default.
- W2113749076 hasConceptScore W2113749076C2779171977 @default.
- W2113749076 hasConceptScore W2113749076C2780427987 @default.
- W2113749076 hasConceptScore W2113749076C2780852908 @default.
- W2113749076 hasConceptScore W2113749076C2781209748 @default.
- W2113749076 hasConceptScore W2113749076C71924100 @default.
- W2113749076 hasConceptScore W2113749076C90924648 @default.
- W2113749076 hasIssue "3" @default.
- W2113749076 hasLocation W21137490761 @default.
- W2113749076 hasLocation W21137490762 @default.
- W2113749076 hasOpenAccess W2113749076 @default.
- W2113749076 hasPrimaryLocation W21137490761 @default.
- W2113749076 hasRelatedWork W136411592 @default.
- W2113749076 hasRelatedWork W180056525 @default.
- W2113749076 hasRelatedWork W1823200579 @default.
- W2113749076 hasRelatedWork W2032853726 @default.
- W2113749076 hasRelatedWork W2053128632 @default.
- W2113749076 hasRelatedWork W2114989931 @default.
- W2113749076 hasRelatedWork W2402385342 @default.
- W2113749076 hasRelatedWork W2405495633 @default.
- W2113749076 hasRelatedWork W2442769633 @default.
- W2113749076 hasRelatedWork W2466209479 @default.
- W2113749076 hasVolume "10" @default.
- W2113749076 isParatext "false" @default.
- W2113749076 isRetracted "false" @default.
- W2113749076 magId "2113749076" @default.
- W2113749076 workType "article" @default.